AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

CEFTRIAXONE USP

9 registrations across 3 African markets— 6 active

Markets with CEFTRIAXONE USP

Recent registrations

Brand / ProductMarketHolderStatusExpires
Oframax 1g injection
Powder for Injection
🇿🇲ZambiaSun Pharmaceutical Industries LimitedactiveDec 2029
SANTRIAX INJECTION🇬🇭GhanaactiveJul 2029
SANTRIAX INJECTION🇬🇭GhanaactiveJul 2029
Ceftatime -1000 injection
Powder for Injection
🇿🇲ZambiaMankind Pharma LtdactiveMay 2029
LEXTRIAX 1G INJECTION (Each vial contains Ceftriaxone USP 1g)🇬🇭GhanaactiveMay 2029
LEXTRIAX 1G INJECTION (Each vial contains Ceftriaxone USP 1g)🇬🇭GhanaactiveMay 2029
INFI-AXONE 1G POWDER FOR INJECTION
POWDER FOR INJECTION
🇲🇼MalawiexpiredMar 2025
XONE-250 250MG INJECTION
INJECTION
🇲🇼MalawiexpiredJun 2009
MARIAXONE 1G INJECTION
INJECTION
🇲🇼MalawiexpiredJun 2005

CEFTRIAXONE USP in Africa — Regulatory Overview

CEFTRIAXONE USP is registered across 3 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Ghana, Malawi, Zambia. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 6 (67%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.